Urovant Sciences Ltd

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom.

Urovant Sciences' interim results from a Phase 2a trial of URO-902 gene therapy were presented at the annual meeting of the American Urological Association (AUA2022).  Urovant is a wholly-owned subsidiary of Sumitovant Biopharma Ltd.

Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo

IRVINE, Calif & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present New Data at the 2021 Annual Meeting of the American Urological Association

Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the 2021 Annual Meeting of the American Urological Association

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the appointment of Betzy Estrada as executive vice president and chief human resources officer. In her new role, Estrada reports to Urovant President and Chief Executive Officer Jim Robinson and is based at the company's headquarters office in Irvine, Calif. “Betzy Estrada joins Urovant Sciences at a time of significant growth and evolution for ou

Urovant Sciences Appoints Betzy Estrada as Executive Vice President and Chief Human Resources Officer

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, a wholly owned subsidiary of Sumitovant, has been named as one of the 2021 Best Places to Work in Orange County.

Urovant Sciences Named One of the 2021 Best Places to Work in Orange County

IRVINE, Calif. & BASEL, Switzerland & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Urovant and Sunovion announce the launch of co-promotion activities for GEMTESA® (vibegron) to extend promotion to primary care physicians.

Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with Overactive Bladder

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Journal of Urology Publishes Clinical Safety & Efficacy Data on GEMTESA (vibegron) in May Issue

Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA® (vibegron), in the Journal of Urology

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder

Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results

Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the DSMB

Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board

NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Urovant Sciences Ltd. (NASDAQ: UROV) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...

SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies -UROV, INFO, WDR, CKH, EIGI

GEMTESA® is the second FDA approval for the Sumitovant Biopharma family of companies in the past weekGEMTESA® is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences GEMTESA® is the second FDA approval for the Sumitovant Biopharma family of companies in the past weekGEMTESA® is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences

Sumitovant Biopharma Announces Urovant Sciences Receives U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg GEMTESA® (vibegron), a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. This approval marks the first new oral branded OAB medication approved by the FDA

Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Urovant Sciences (NasdaqGS: UROV) to Sumitovant Biopharma. Under the terms of the proposed transaction, shareholders of Urovant will receive only $16.25 in cash for each share of Urovant that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whethe

UROVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Urovant Sciences - UROV

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--UROV Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint

Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study

Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study

New York, New York--(Newsfile Corp. - November 18, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/68512_8fde49d774094aee_001full.jpgTo: All Persons or Entit

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Urovant Sciences Ltd. to Sumitovant Biopharma

BERWYN, Pa., Nov. 18, 2020 /PRNewswire/ -- RM LAW, P.C. announces an investigation on behalf of Urovant Sciences Ltd. ("Urovant" or the "Company") (NASDAQ: UROV) regarding possible breaches of fiduciary duties and other violations of law related to Urovant's agreement to be acquired by...

RM LAW Announces Investigation of Urovant Sciences Ltd.

The acquisition of Urovant Sciences by majority owner Sumitomo significantly undervalues the company's lead asset vibegron. The buyout price implies approximately $250 million in peak sales for vibegron in the OAB market.

Urovant Sciences: Buyout Price Is Too Low

NEW YORK, Nov. 13, 2020 /PRNewswire/-- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Urovant Sciences Ltd. ("Urovant" or the "Company") (UROV) relating...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Urovant Sciences Ltd. - UROV

NEW YORK, Nov. 13, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Urovant Sciences Ltd. ("UROV" or the "Company") (NASDAQ: UROV) in connection with the proposed interested-party acquisition of...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd.

The company's biggest shareholder plans to acquire all of Urovant.

Why Urovant Sciences Stock Is Skyrocketing Today

Urovant Sciences (UROV) has entered into an acquisition agreement with Sumitovant Biopharma that has UROV stock soaring on Friday. The post UROV Stock: 9 Things to Know About the Urovant Sciences-Sumitovant Deal appeared first on InvestorPlace.

UROV Stock: 9 Things to Know About the Urovant Sciences-Sumitovant Deal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Urovant Sciences Ltd. (NASDAQ: UROV) to Sumitovant Biopharma Ltd. for $16.25 per share is fair to Urovant shareholders. On behalf of Urovant shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. If you are an Urovant shareholder and would like to d

Urovant Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Urovant Sciences Ltd. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – UROV

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares

Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares

NEW YORK and LONDON and IRVINE, Calif. and BASEL, Switzerland, Nov. 12, 2020 /PRNewswire/ -- Sumitovant Biopharma and Urovant Sciences (Nasdaq: UROV) today announced that they have entered into a definitive merger agreement for Sumitovant to acquire the outstanding shares of Urovant...

News for Urovant Sciences Ltd Stock (UROV)